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Prognostic factors for chronic headache
A systematic review
ABSTRACT
Objective: To identify predictors of prognosis and trial outcomes in prospective studies of people
with chronic headache.
Methods: This was a systematic review of published literature in peer-reviewed journals. We
included (1) randomized controlled trials (RCTs) of interventions for chronic headache that re-
ported subgroup analyses and (2) prospective cohort studies, published in English, since 1980.
Participants included adults with chronic headache (including chronic headache, chronic migraine,
and chronic tension-type headache with or without medication overuse headache). We searched
key databases using free text and MeSH terms. Two reviewers independently extracted data and
assessed the methodologic quality of studies and overall quality of evidence identified using
appropriate published checklists.
Results: We identified 16,556 titles, removed 663 duplicates, and reviewed 199 articles, of
which 27 were included in the review—17 prospective cohorts and 10 RCTs with subgroup
analyses reported. There was moderate-quality evidence indicating that depression, anxiety, poor
sleep and stress, medication overuse, and poor self-efficacy for managing headaches are poten-
tial prognostic factors for poor prognosis and unfavorable outcomes from preventive treatment in
chronic headache. There was inconclusive evidence about treatment expectations, age, age at
onset, body mass index, employment, and several headache features.
Conclusions: This review identified several potential predictors of poor prognosis and worse out-
come postinterventions in people with chronic headache. The majority of these are modifiable.
The findings also highlight the need for more longitudinal high-quality research of prognostic fac-
tors in chronic headache. Neurology® 2017;89:291–301
GLOSSARY
BMI5 body mass index; CDH5 chronic daily headache; GRADE5 Grading of Recommendations Assessment, Development
and Evaluation; HIT 5 Headache Impact Test; HMSE 5 headache management self-efficacy; RCT 5 randomized controlled
trial.
Chronic headache—headache occurring on 15 or more days per month for at least 3 months1—
is a major cause of pain and disability. Chronic migraine affects around 1%–4% of the pop-
ulation2,3 and chronic tension-type headache about 2.2%.4 Approximately 25%–50% of those
affected also have medication overuse headache, which has a population prevalence of 1%.5
Chronic headache is a severely disabling long-term condition, with higher symptom frequency
and severity than episodic headache.6
A wide range of demographic, clinical, psychological, and social factors may affect prognosis
and treatment outcome for people with chronic headache.7,8 Our aims were to identify factors
that predict poor prognosis or are associated with differential treatment outcomes from
From the Department of Psychology (K.P., H.B., F.C., T.P.), Royal Holloway, University of London; Warwick Clinical Trials Unit (D.M., M.U.),
Warwick Medical School, University of Warwick, Coventry; and Headache Group (M.M.), Institute of Neurology and The National Hospital for
Neurology and Neurosurgery, Queen Square, London, UK.
Coinvestigators are listed at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 291
preventive treatment in patients with chronic
headache. Factors can be differentiated
between predictors of prognosis and modera-
tors or mediators of treatment outcome.9 Spe-
cifically; predictors are factors, measured at
baseline, that affect outcome but do not inter-
act with the intervention; moderators are fac-
tors, measured at baseline, that interact with
the treatment to change outcome for a sub-
group of participants; mediators are factors
measured during or after treatment that influ-
ence outcomes, with or without interaction
with the treatment.
Identifying those factors may improve the
effectiveness and cost-effectiveness of future
interventions for people living with chronic
headache.10
METHODS This study was prospectively registered with the Inter-
national Prospective Register of Systematic Reviews; PROSPERO
2015: CRD42015019848 (available at crd.york.ac.uk/
PROSPERO/display_record.asp?ID5CRD42015019848).
Identification of studies. We searched for English-language
publications reporting randomized controlled trials (RCTs) or
prospective cohort studies that reported on predictors, moderators,
or mediators of outcome from peer-reviewed journals in Cochrane,
MEDLINE/PubMed, Embase, PsychINFO, Web of Science, and
ASSIA, supplemented by backward citation tracking, from January
1, 1980, to February 12, 2015. We updated the search on June 14,
2016 (appendix e-1 and table e-1 at Neurology.org).
We included RCTs with at least 20 patients per treatment
arm at follow-up (in line with previous research11) that either
(1) investigatedmoderators or mediators of outcome using a priori
hypotheses or (2) analyzed subgroups post hoc; and prospective
cohort studies that measured factors at baseline and used a time-
line to outcomes at follow-up to explore the associations between
factors. Study participants were adults (18 years and over) and
had chronic headache as defined by the International Classifica-
tion of Headache Disorders1 with at least 15 headache days/
month for at least 3 months. We included chronic headache,
chronic migraine, and chronic tension-type headache, with or
without medication overuse headache.
In RCTs that included episodic headache patients, at least
50% of the study population had to be chronic headache patients.
In prospective cohort studies, prognostic factors had to be ana-
lyzed and reported separately for chronic headache. We excluded
cross-sectional and prevalence studies, case-control studies, and
studies that included any other chronic pain conditions. We used
EPPI reviewer4 software to screen studies for inclusion/exclusion
by title and abstract. Articles for possible inclusion were assessed
in full. We extracted data from included studies on separate pre-
developed forms for RCTs and prospective cohort studies sepa-
rately, including the following items: author, year, title,
headache type, number of participants, description of interven-
tion and control groups (as applicable), factors assessed as poten-
tial predictors/moderators/mediators, outcomes, and results.
Quality assessment. RCTs were quality assessed with a set of
questions adapted from the Cochrane Collaboration risk of bias
tool12 and we excluded any studies that yielded a high risk of bias
score. We assessed sequence generation, allocation concealment,
incomplete outcome data, and blinding of outcome assessment.
Studies scoring 4–5 points were considered high quality, studies
scoring 2–3 were considered medium quality, and studies that
scored 0 or 1 were excluded. We assessed the level of evidence from
subgroup analyses using the methodologic criteria for the assess-
ment of moderators in systematic reviews of RCTs,13 which score
for a priori planned analysis, theory-driven selection of factors,
measurement of moderators prior to randomization, quality of
moderator measures, and explicit test of the interaction between
moderator and treatment. Studies complying with all 5 criteria were
considered as providing confirmatory evidence; those complying
with criteria 3, 4, and 5 as providing exploratory evidence. All other
studies were classified as providing insufficient evidence.
Methodologic quality coding of prospective cohort studies
was carried out based on recommendations for evaluation of
the quality of prognosis studies in systematic reviews.14 We as-
sessed if sampling frame and recruitment been described ade-
quately, the frequency of loss to follow-up from sample,
definition of outcomes of interest, if appropriate analyses were
used, if statistical reporting was appropriate, if sample size was
appropriate for statistical analysis, if measurement of all important
confounders was adequately valid and reliable, and if most impor-
tant baseline measures were included. We scored 1 point per
item; studies scoring #5 points were considered low quality,
studies scoring 6–9 points medium quality, and those scoring
$10 out of 14 possible points were considered high quality.
Finally, we assessed the overall quality of evidence for each
potential factor with an adapted version of the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
framework,15 considering phase of investigation, methodologic
quality per studies, and potential inconsistency, indirectness,
imprecision, publication bias, dose response effect, or potentially
large effect sizes across all studies. We downgraded factors for
inconsistency when estimates of the prognostic factor’s associa-
tion with outcomes varied in direction. We downgraded factors
for indirectness when the included sample of most studies only
represents a subset (i.e., chronic migraine only, or chronic
tension-type headache only, or medication overuse headache on-
ly) of the whole population of interest (chronic headache). We
downgraded quality for imprecision if the evidence was generated
by few studies involving a small number of participants and most
of the studies provided imprecise results or no relevant statistics or
if evidence only was provided by single studies.
Data synthesis. Because of the high heterogeneity among stud-
ies regarding treatment and investigated prognostic factors, it was
not possible to pool studies in a meta-analysis. We therefore
present a narrative synthesis of the results, considering the overall
quality of evidence as proposed by Huguet et al.15
RESULTS We identified 16,556 titles through data-
base searches and removed 633 duplicates. A total of
15,923 studies were screened by title and abstracts
and 15,724 records excluded. The remaining records
were grouped into RCTs (126) and prospective
cohort studies (73). After full text assessment, 27
studies were included (10 RCTs with subgroup anal-
ysis16–25 and 17 prospective cohorts5,26–41) (figure).
Characteristics of included studies. Eight studies tested
a general population of “chronic headache,” 8 are
specifically on “chronic migraine,” 5 include partic-
ipants with “chronic daily headache,” 3 are
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specifically on “chronic tension type headache,” and 3
on “chronic headache forms with medication over-
use.” Outcomes assessed include headache-specific
measures (headache frequency, intensity, and dura-
tion of headache attacks); measures of quality of life
or headache-related disability; mood; coping and
headache management self-efficacy (HMSE); days off
work; persistence of chronic headache or reverting to
episodic headache; relapse rates (from withdrawal
therapy); or response to preventive treatment in
responder analyses (table 1).
Randomized controlled trials. Six of the 10 included
trials involved medication in at least one of their treat-
ment arms.16,20–25 Two studies examined subgroups
in trials of psychological interventions,17,20 with one
study doing this alongside medication treatment.20
One study assessed manual therapy,18 while 3 studies
looked at acupuncture.19,22,23 Within the subgroup
analyses in included RCTs, only 3 studies assessed
potential moderators by providing an explicit interac-
tion test with treatment.19,20,23 All other RCTs pro-
vide, in the absence of an interaction test, findings
about predictors of outcome only.
Prospective cohorts. The majority of the prospective
cohort studies assessed potential predictors of
response to treatment or withdrawal therapy outcome
(n 5 11), while 6 assessed predictors of prognosis,
independent of treatment.
Methodologic quality. Of the 10 RCTs with subgroup
analyses and of at least medium overall methodologic
quality (table 2), only one study provided confirma-
tory evidence (based on methodologic assessment of
subgroup analysis). Two studies provided exploratory
evidence, and the remaining 7 provided insufficient
evidence as they did not use an explicit interaction
test, did not measure subgroup factor prior to ran-
domization, or failed to measure subgroup factors by
adequate (reliable and valid) measurements (table 3).
Of the 17 observational studies, 5 were of high
methodologic quality, 10 were medium quality, and
2 were low quality (table 4).
Overall quality of evidence.The GRADE assessment re-
sulted in an initial rating of the evidence for specific
factors based on the phase of investigation of the stud-
ies. The majority of included studies consisted of
phase 1, described as exploratory studies.15 We did
not rate any factors as overall high-quality evidence,
as none of our factors had been investigated in a large
number of cohort studies that were designed to con-
firm a hypothesized independent effect of the factor
on the outcome (phase 2 study) or to test a conceptual
model, which explains its underlying mechanisms
(phase 3 study).We did not upgrade the quality of any
factor for a dose response effect or a large effect size.
The initial rating per factor was further down-
graded, as applicable, based on the methodologic
Figure Study flowchart
RCT 5 randomized controlled trial.
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Table 1 Characteristics of included studies
Author and
year Country
Study
sample size
Description of
intervention (and control
group) if applicable
Type of
headache Study type
Phase of
investigation
Prognostic
factor type
Methodologic
quality
Boe 2007 Norway 102 Prednisolone or placebo CH RCT with subgroup
analysis
1 Predictor of
outcome
1
Boe 2009 Norway 80 Prednisolone or placebo CDH (with
MO)
RCT with subgroup
analysis
1 Predictor of
outcome
1
Bromberg
2012
USA 189 Web-based behavioral
intervention vs waiting
list
CM RCT with subgroup
analysis
1 Predictor of
outcome
11
Castien 2011 Netherlands 82 Manual therapy or usual
care
CTTH RCT with subgroup
analysis
1 Predictor of
outcome
1
Ellis 2004 UK 401 Acupuncture or usual
care
CH RCT with subgroup
analysis
1 Moderator 1
Holroyd 2009 USA 203 Placebo vs tricyclic
antidepressant
medication vs cognitive
behavioral stress
management therapy
with placebo vs stress
management therapy 1
antidepressant
medication
CTTH RCT with subgroup
analysis
3 Moderator/
mediator
111
Schulte-
Mattler 2004
Germany 107 Botulinum toxin A vs
placebo
CTTH RCT with subgroup
analysis
1 Predictor of
outcome
1
Yang 2011 Taiwan 66 Acupuncture vs
topiramate
CM RCT with subgroup
analysis
1 Predictor of
outcome
1
Yang 2013 Taiwan 66 Acupuncture vs
topiramate
CM RCT with subgroup
analysis
1 Moderator 11
Yurekeli 2008 Turkey 70 Sodium valproate vs
placebo
CDH RCT with subgroup
analysis
1 Predictor of
outcome
1
Bigal 2005 USA 176 Prophylactic medication CM Observational cohort
(clinic-based)
2 Predictor of
outcome
11
Buse 2011 USA 7,169 NA CM Observational cohort
(population-based)
1 Predictor of
prognosis
111
Eross 2005 USA 61 Botulinum toxin A CM Open-label 1 Predictor of
outcome
11
Fontanillas
2010
Spain 72 Prophylactic medication CDH (with
MO)
Long-term outcome
study
1 Predictor of
outcome
1
Gaul 2011 Germany 841 NA CH Long-term outcome
study
1 Predictor of
outcome
111
Houle 2012 USA 55 NA CH Observational cohort 2 Predictor of
prognosis
111
Katsarava
2003
Germany 98 NA CH Long-term outcome
study
1 Predictor of
outcome
11
Katsarava
2004
Germany 96 NA CH Long-term outcome
study
1 Predictors of
outcome
11
Louter 2013 Netherlands 2,331 NA CM Observational cohort 1 Predictor of
prognosis
11
Lu 2001 Taiwan 108 NA CDH Observational cohort 1 Predictor of
prognosis
11
Luconi 2007 Italy 168 Prophylactic medication CM Observational cohort
(clinic-based)
2 Predictor of
outcome
11
Lundqvist
2011
Norway 195 NA CH Observational cohort 2 Predictor of
prognosis
11
Matthew 2007 USA 82 Botulinum toxin A CDH Open-label 1 Predictor of
outcome
1
Seok 2006 Korea 136 Prophylactic medication CDH Open-label 1 Predictor of
outcome
11
Tribl 2001 Austria 55 NA CDH Long-term outcome
study
1 Predictor of
outcome
11
Continued
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quality of the studies and potential inconsistency,
indirectness, and imprecision of findings (table 5).
We present prognostic factors identified together
regardless of the type of factor (predictor or modera-
tor, mediator).
Potential prognostic factors with moderate-quality
evidence. Depression and anxiety. Depression was consis-
tently found to be a predictor of poor outcome.
Depression predicted higher influence of headaches
on normal daily life and ability to function (Headache
Impact Test [HIT]–6 scores)27 and having allodynia,
more migraine days, a larger change in migraine
days from baseline to follow-up and more medication
days at follow-up,34 lower response to prophylactic
treatment,35 lower response to prednisolone 1 with-
drawal therapy,25 and one study found that there was
reduced response to placebo treatment when anxiety or
mood diagnosis was present.20 However, the same study
also found that people with mood disorder benefit more
from antidepressant therapy and behavioral therapy.
Medication overuse.Medication overuse was also con-
sistently found to predict poor prognosis. Medication
overuse predicted the presence of chronic headache
at follow-up,5,36,38,41 increase in headache days,34 lower
quality of life,29 and unsuccessful detoxification.29,40
Headache management self-efficacy. Only one study20
investigated a potential effect mediator within its
analysis. The authors measured HMSE during the
intervention (2 months postrandomization) and
found it mediated the effects of antidepressant ther-
apy and stress management therapy on headache-
related disability and headache activity.
Sleep and stress. One study found that poor sleep
and high stress predict headache severity in individu-
als with chronic headache. Conversely, high sleep and
low stress showed a protective effect.31
Potential prognostic factors with low-quality evidence.
Higher expectations. In both the acupuncture and topir-
amate groups in one study,23 it was found that those
with a higher general expectation of treatment showed
a greater reduction in moderate or severe headache
days compared to those with lower expectations.
Body mass index. A higher body mass index (BMI)
did not predict more severe HIT-6 scores,27 having
allodynia, headache frequency, medication use,34 or
response to multidisciplinary treatment.30 However,
Table 1 Continued
Author and
year Country
Study
sample size
Description of
intervention (and control
group) if applicable
Type of
headache Study type
Phase of
investigation
Prognostic
factor type
Methodologic
quality
Zidverc-
Trajkovic 2007
Serbia 240 Prophylactic medication CH (with
MO)
Open-label 1 Predictor of
outcome
111
Zwart 2003 Norway 32,067 NA CH Observational cohort 2 Predictor of
prognosis
111
Abbreviations: CDH 5 chronic daily headache; CH 5 chronic headache; CM 5 chronic migraine; CTTH 5 chronic tension-type headache; MO 5 medication
overuse; NA 5 not applicable; RCT 5 randomized controlled trial.
Methodologic quality: for RCT subgroup analyses: 1 5 insufficient evidence; 11 5 exploratory evidence; 111 5 confirmatory evidence; for observational
studies: 1 5 low quality; 11 5 medium quality; 111 5 high quality.
Table 2 Risk of bias assessment in randomized controlled trials
Author and year
1. Did the study have an
adequate randomization
sequence?
2. Was allocation
concealment carried
out?
3. Were withdrawals
and dropouts explained?
4. Was outcome
assessment blinded?
5. Sufficient numbers
(>20 in each arm)? Score
Boe 2007 ✓ ✓ ✓ ✓ ✓ 5
Boe 2009 ✓ ✓ ✓ ✓ ✓ 5
Bromberg 2012 ✓ ✓ ✓ 3
Castien 2011 ✓ ✓ ✓ ✓ 4
Ellis 2004 ✓ ✓ ✓ 3
Holroyd 2009 ✓ ✓ ✓ 3
Schulte-Mattler
2004
✓ ✓ ✓ 3
Yang 2013 ✓ ✓ ✓ ✓ 4
Yang 2011 ✓ ✓ ✓ ✓ ✓ 5
Yurekeli 2008 ✓ ✓ 2
Studies scoring 4–5 points were considered higher quality (low risk of bias); studies scoring 2–3 were considered medium quality (moderate risk of bias).
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conversely, one study found that a higher BMI pre-
dicted a better response to preventive treatment and
favorable HIT-6 scores postintervention.25
Age. Older age had no effect on the response to in-
terventions, including prophylactic treatment,25,35 web-
based behavioral intervention,17 and acupuncture.23
Older age was also not associated with reverting from
chronic to episodic migraine,38 response to medication
overuse,29 having allodynia,34 headache frequency or
intensity,39 or headache-related disability.20
In contrast, older age was found to predict worse
HIT-6 scores,27 later chronic daily headache (CDH),5
lower response to botulinum toxin A treatment,28
unsuccessful detoxification,40 and more weekly analge-
sics used.41 Conversely, one study found that older
patients had better outcomes from multidisciplinary
treatment.30
Age at onset. Older age at onset was a predictor for
fewer migraine days, less use of medication at follow-
up,34 and better response to prophylactic medica-
tion,40 but did not predict response to prophylactic
treatment in another study.35
Baseline headache-related disability.Higher symptoms
at baseline were found to predict higher rates of dis-
ability27 and the transition to CDH.5 In contrast,
higher symptoms and disability at baseline were asso-
ciated with successful detoxification,40 and showed no
significant association with response to treatment.35
Baseline headache frequency. The evidence from 7
studies was contradictory. Headache frequency did
not differ between responders and nonresponders to
prophylactic treatment,35 and higher baseline fre-
quency did not predict reverting to episodic migraine
from chronic migraine after treatment.38 It was not
related to subsequent HIT-6 scores26 in patients with
chronic migraine. Conversely, higher headache fre-
quency was related to later persistent chronic head-
ache,5 was found to increase the risk of having
allodynia and more medication use days, but was also
associated with a reduction in migraine days at follow-
up.34 Two studies found that higher frequency predicts
favorable response to detoxification40 and to multidis-
ciplinary treatment.30
Baseline headache severity. One study20 found that
when looking at headache index as outcome, those
with more severe headache had better treatment ef-
fects from stress management and antidepressant
therapy than those with less severe headache. Another
study23 found that those with more than 20 moderate
or severe headache days a month had a greater reduc-
tion in the mean number of moderate or severe head-
ache days after acupuncture.
Employment. One study found that those who were
employed had higher response rates to treatment com-
pared to those on medical leave,40 but 2 studies25,38
found employment made no difference for persistence
of CDH and number headache days at follow-up.
The evidence for all other factors was graded as
very low quality (table 5).
DISCUSSION Summary of results. In this review,
we aimed to systematically identify predictors, mod-
erators, and mediators of prognosis and outcomes
in chronic headache from prospective studies, includ-
ing prospective cohorts and trials of preventive inter-
ventions. Our findings suggest with moderate-quality
evidence that depression/anxiety, medication overuse,
poor sleep, high stress, and low HMSE are associated
with worse outcomes. Lower-quality evidence suggests
that higher expectations, age, age at onset, headache
Table 3 Quality assessment of randomized controlled trial subgroup analyses using methodologic criteria by Pincus et al.13
Author and year
Was subgroup
specified a priori?
Was selection of subgroup
factors theory/evidence
driven?
Subgroup factors
measured prior to
randomization?
Were subgroup factors
measured by reliable and
valid measurements?
Was an explicit test
of the interaction
used?
Level of
evidence
Boe 2007 Insufficient
Boe 2009 ✓ ✓ Insufficient
Bromberg 2012 ✓ ✓ ✓ ✓ Exploratory
Castien 2011 ✓ ✓ Insufficient
Ellis 2004 ✓ Insufficient
Holroyd 2009 ✓ ✓ ✓ ✓ ✓ Confirmatory
Schulte-Mattler
2004
✓ Insufficient
Yang 2011 ✓ ✓ ✓ Insufficient
Yang 2013 ✓ ✓ ✓ Exploratory
Yurekeli 2008 ✓ ✓ ✓ Insufficient
Confirmatory evidence: Studies complying with all 5 criteria; exploratory evidence: studies complying with criteria 3, 4, and 5. All other studies were
classified as providing insufficient evidence.
296 Neurology 89 July 18, 2017
frequency, intensity, BMI, disability scores, and
employment are potential predictors. The highest-
quality evidence we found suggests that psychosocial
factors, anxiety and mood disorder, sleep and stress,
and HMSE are potential prognostic factors. This is
an important finding, as these factors are all potentially
modifiable. Specifically, groups with low mood (anxi-
ety and mood disorder) appear to respond better to
antidepressants and stress management therapy. In the
absence of anxiety and mood disorder, higher HMSE
improves treatment outcomes. We also found some
evidence that more positive expectations about treat-
ment are associated with better outcomes. Our results
also suggest that older patients and those with more
severe headache might benefit from multidisciplinary
treatment, which can address comorbidity and specifi-
cally tailor treatment to more complex needs. However,
owing to the limited number of studies, it was not
possible to identify prognostic factors from studies
providing high-quality evidence. The number of studies
identified matching our inclusion criteria for this review
was low and overall quality of evidence was moderate,
low, or very low, implying that confidence in the esti-
mate is low.
Comparison with other studies and reviews. While most
of the evidence on prognostic factors in the field focuses
on studying the chronification process of headache or
risk factors of developing chronic headache from epi-
sodic headache, we looked at patients with a diagnosis
of chronic headache at baseline. Our findings indicate
that there is potential for behavioral interventions tar-
geting psychosocial prognostic factors in people living
with chronic headache. Our results are in line with
Smitherman et al.,42 who suggest that depression,
anxiety, and insomnia should be assessed in every
treatment-seeking headache patient, particularly those
with frequent attacks.42 Our finding that self-efficacy
can mediate treatment effects in chronic headache is in
line with Peck and Smitherman,43 who assessedHMSE
as mediator for the relationship between headache
severity and disability in a population of predominantly
nonchronic headache sufferers. Self-efficacy has also
been found to be associated with improvement of
outcomes in other chronic pain conditions.44–46
Strengths and limitations of this review. The strength of
this review is that we only included prospective longi-
tudinal study types to ensure reliability and quality of
results. These study designs are less prone to some
types of bias and can most strongly suggest causa-
tion.47 For the widest feasible scope and to identify
all potential prognostic factors, we included RCTs
with subgroup analyses, which are the ideal study
Table 4 Methodologic quality of prospective cohort studies using methodologic criteria by Hayden et al.14
Author and year
Adequate
description of
sampling?
Attrition
reported?
Outcome of
interest
reported?
Appropriate
analyses?
Reporting of
analyses
appropriate?
Adequate
sample size?
Valid
measure of
confounders?
No. of most
important
baseline
measures
reported as
total? (total/7)
Total/
14
Bigal 2005 P N Y Y N Y Y 4 8.5
Buse 2012 Y N Y Y Y Y Y 5 11
Eross 2005 Y Y Y Y Y Y N 3 9
Fontanillas 2010 N Y N Y N Y N 2 5
Gaul 2011 Y N Y Y Y Y Y 5 11
Houle 2012 Y Y Y Y Y Y Y 4 11
Katsarava 2003 N Y Y Y N Y N 3 7
Katsarava 2004 N Y Y Y N Y N 3 7
Louter 2013 Y Y Y Y Y Y Y 4 11
Lu 2001 Y Y Y Y Y Y Y 2 9
Luconi 2007 Y Y Y Y N N N 5 9
Lundqvist 2011 Y Y Y Y N Y Y 2 8
Matthew 2007 N N Y Y N Y N 2 5
Seok 2006 Y Y Y Y P N Y 3 8.5
Tribl 2001 Y N Y Y N N Y 5 9
Zidverc-
Trajkovic 2007
Y Y N Y Y Y Y 7 13
Zwart 2003 Y N Y Y Y Y Y 4 10
#5 Points 5 low quality; 6–9 points 5 medium quality; $10 points 5 high quality; N 5 no (0 points); P 5 partially (0.5 point); Y 5 yes (1 point).
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Table 5 Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile of overall quality
Potential prognostic factors
No. of
studies
GRADE factors
No. of
participants
Univariate or
multivariate
Phase of
investigation
Overall
qualityStudy limitations Inconsistency Indirectness Imprecision 1 0 2
Psychosocial factors
Depression and anxiety 5 ✓ ✓ X ✓ 9,951 5 1 and 3 111
Employment 3 X ✓ X X 456 1 2 1 11
Higher expectations 1 X ✓ X X 66 1 1 11
Headache management self-
efficacy
1 ✓ ✓ X X 203 1 3 111
Sleep and stress 1 ✓ ✓ ✓ X 80 1 2 111
Headache features
Allodynia 3 X ✓ X X 2,479 1 1 1 1
Muscle tenderness 3 X X X X 250 1 2 1 1
Throbbing 1 X ✓ X X 66 1 1 1
Unilateral headache 2 X X X X 148 1 1 1 1
Demographics
Age at onset 3 ✓ X X X 2,739 2 1 1 11
BMI 4 ✓ X X ✓ 10,522 3 1 1 and 2 11
Age 15 ✓ X ✓ ✓ 43,640 1 9 5 1, 2, and 3 11
Headache characteristics
Migraine as subgroup 4 X X X X 619 2 2 1 1
Headache severity 2 X ✓ X 269 2 1 and 3 11
Headache-related disability 4 ✓ X X X 7,685 1 3 1 and 2 11
Headache frequency 7 ✓ X X ✓ 4,000 2 3 2 1 and 2 11
Medication overuse 7 ✓ ✓ X ✓ 36,215 7 1 and 2 111
Drug type overused (ergots) 2 X X X X 240 1 1 1 1
Drug type overused (analgesics) 3 X X X X 266 1 1 1 1
Abbreviation: BMI 5 body mass index.
For univariate and multivariate analyses:15 number of significant effects with a positive value; 05 number of nonsignificant effects;25 number of significant effects with a negative value. For GRADE factors:
✓ 5 no serious limitations; X 5 serious limitations or unclear (unable to rate based on available information). For overall quality: 1 5 very low quality; 11 5 low quality; 111 5 moderate quality.
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design to assess potential moderators and mediators of
outcome, and prospective cohort studies (including
observational cohort studies, long-term outcome
studies, and open-label studies), which are the best
study designs to assess predictors of prognosis inde-
pendent of treatment. It would have been favorable to
be able to analyze predictors, moderators, and me-
diators separately; however, the large heterogeneity
between factors measured and scarcity of data did not
allow us to do this and we presented factors measured
by studies together regardless of the type of prog-
nostic factors.
We adhered to our registered protocol, thus
strengthening the credibility of the evidence synthesis.
We assessed the methodology of included studies
with the best available tools specific to the study
designs of included primary studies and judged
and reported the overall quality of the evidence based
on the recommendations from the GRADE
Working Group. The GRADE framework adapted
to prognostic factor research is the best available tool
for reporting the overall quality of the evidence of
the potential prognostic factors since we could not
carry out meta-analysis.
With regards to included participants, we rigor-
ously only included studies on chronic headache
types, with a chronic headache diagnosis as baseline,
so the results are specific to this group of patients.
Most of the research in the field reports on episodic
headache, which has a much higher prevalence, but
prognostic factors established in episodic headache
are not necessarily transferable to chronic headache
patients.
Limitations regarding the interpretation of the find-
ings from this study should be taken into consider-
ation. As we included more than one form of
chronic headache, most of our findings are subject to
some indirectness, as some findings came from studies
specific for chronic tension-type headache, chronic
migraine, or chronic medication overuse headache,
and therefore we urge some caution with generalizabil-
ity of findings for all forms of chronic headache. We
could not present results for each of the included diag-
nostic groups separately because of a scarcity of data
and some of the included primary studies including
mixed groups and presenting overall results.
Publication bias is one of the most common biases
in systematic reviews. As suggested by Huguet et al.,15
we considered publication bias to exist across all factors
as we did not have determinate factors investigated in
large numbers of cohort studies purposefully designed
to confirm hypothesized factors, and we therefore con-
sequently downgraded the overall evidence.
Judging the overall quality of evidence per factor
was difficult, as measurements used to assess the same
factors were not necessarily related to the same out-
comes. Furthermore, most study samples are small
and factors were measured by single studies or a small
amount of studies with comparatively small patient
groups assessed. The included RCTs were underpow-
ered for moderator analysis, which creates some
imprecision of results, and relevant statistics were
not consistently reported. Studies with otherwise
good methodology were compromised by poor meth-
odologic quality of their subgroup analysis. We spe-
cifically note the lack of RCTs that carried out
prespecified subgroup analysis, which would provide
higher-quality evidence, and the lack of theoretical
framework of moderator and mediator analyses.43,48
In this review, there was only one study that con-
ducted prespecified subgroup analysis, and its report-
ing was difficult to interpret. The authors concluded
that the moderator was significantly associated with
treatment outcome before, during, and after treat-
ment, but it was not clear if the significance was
driven by the difference between placebo and the
other 3 treatments across treatment time or the dif-
ference within treatment across treatment time. The
mediator analysis reported in the same article adjusted
for some covariates but there remains the potential for
confounding of the mediator outcome association by
other factors. Most of the included cohort studies did
not specify the relationships they were testing a priori,
and were therefore defined as phase I explanatory
studies.
Implications for future research and clinical practice.
Overall this review identified several potentially modifi-
able prognostic factors in chronic headache. However,
the review findings also indicate that the evidence is
scarce. No high-quality evidence was provided for any
of the potential prognostic factors; therefore, no defi-
nite clinical conclusion can be drawn about factors
predicting the prognosis of patients living with chronic
headache or factors that influence or predict treatment
response. The implication is that future research on
prognostic factors in chronic headache should be
ideally conducted as large, prospective, registered, and
protocol-based studies with sufficient study populations
and transparent reporting. Prespecified prediction
analyses in large cohort studies are needed to confirm
potential predictors. Further, a priori analysis plans for
subgroups in RCTs are needed to assess moderators
and mediators of treatment outcome.
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